- 
French
 - 
fr
Spanish
 - 
es
English
 - 
en

Follow Us:

Obesity and Colorectal Cancer: The Hidden Role of Belly Fat

Nov 17, 2026

By Yvonne Rodríguez, MSc – Clinical Nutritionist, Founder and Chief Nutritional Officer, Smart Nutrition International

The link between obesity and colorectal cancer has never been more relevant. Colorectal cancer, often called bowel cancer, is no longer only a disease of later life. In Spain it is projected to be the most frequently diagnosed cancer in 2026, with an estimated 44,132 new cases, ahead of breast, lung and prostate cancer. Across Europe, the Americas and Asia, diagnoses are rising fastest in adults under 50. That is the same generation in which excess body fat has increased most sharply.

This article combines that work with the most important studies published in 2025 and 2026. It is written for patients who want to understand their risk and for colleagues who want a concise, evidence-based update.

The central message is encouraging. Most of what connects excess weight to bowel cancer can be changed: where we store fat, what we eat, how our gut bacteria respond, and how much muscle we keep.

Key takeaways

  • Obesity raises colorectal cancer risk by roughly 30%, and abdominal (visceral) fat is a stronger predictor than body mass index (BMI).
  • Being overweight or obese is now firmly linked to early-onset colorectal cancer, diagnosed before the age of 50.
  • Visceral fat drives tumour growth through insulin, inflammation, hormones made by fat tissue and changes in the gut microbiome.
  • Ultra-processed foods, processed meat and low-fibre diets increase risk; legumes, wholegrains and a varied, plant-rich diet lower it.
  • Muscle matters: structured exercise after treatment improved survival in a landmark 2025 trial.

Obesity and colorectal cancer: what the latest research says

The evidence that obesity increases colorectal cancer risk is consistent and long-standing. The International Agency for Research on Cancer (IARC) concluded in 2016, after reviewing more than 1,000 studies, that a high BMI raises risk by around 30%. A meta-analysis of 41 prospective cohorts found a relative risk of 1.33 for obesity measured by BMI, but 1.46 when abdominal obesity was measured by waist circumference. An umbrella review in the BMJ estimated that every 5 kg/m² increase in BMI raises colon cancer risk by 30% in men and 9% in women.

What has changed is our understanding of early-onset colorectal cancer. In the US Nurses’ Health Study II, women under 50 with obesity had almost double the risk of developing colorectal cancer compared with women of healthy weight. A 2026 systematic review and meta-analysis in the Scandinavian Journal of Gastroenterology has now confirmed this across cohorts: overweight and obesity combined increased early-onset risk by 59% (OR 1.59), with a smaller effect for overweight alone (OR 1.24) and a stronger one for obesity.

A 2025 analysis of more than 30,000 US adults aged 18 to 49 added an important detail. People with early-onset disease had a larger waist circumference and body roundness index, which suggests that fat distribution matters, not just weight on the scales. Meanwhile, global burden data published in 2025 show that early-onset cases attributable to high BMI are shifting towards low- and middle-income countries, including much of Latin America.

StudyPopulationKey finding
IARC Working Group, 2016More than 1,000 studiesHigh BMI: around +30% risk
Ma et al., 201341 cohorts (BMI); 13 cohorts (waist)RR 1.33 for BMI; RR 1.46 for waist circumference
Liu et al., 201985,256 womenEarly-onset risk almost doubled with obesity (RR 1.93)
Scand J Gastroenterol, 2026Cohort meta-analysisBMI ≥ 25: OR 1.59 for early-onset disease

Not all fat is equal: why visceral fat matters most

There is not one obesity, but many. BMI is useful for populations, yet it cannot tell fat from muscle or show where fat is stored. Two people with the same BMI can have very different risk profiles.

In clinical practice, several simple measures tell us more:

  • Waist circumference reflects abdominal fat and is more closely linked to colorectal cancer than BMI.
  • Waist-to-hip ratio distinguishes the higher-risk “apple” (android) pattern from the “pear” (gynoid) pattern.
  • Sagittal abdominal diameter is a quick marker of visceral fat in the consulting room.
  • Bioimpedance (BIA), DXA and CT scans measure fat mass, lean mass and visceral fat, and can detect sarcopenia (loss of muscle mass).

Visceral fat, which surrounds the internal organs, is the most dangerous kind. It is metabolically active and drains directly into the liver through the portal vein, releasing hormones and inflammatory signals that affect the whole body, including the lining of the colon.

How excess body fat fuels tumour growth: four biological pathways

Visceral adipose tissue behaves like an endocrine organ. It influences colorectal cancer through four connected pathways:

  1. The insulin/IGF-1 axis. High insulin levels increase free IGF-1, which makes colon cells divide faster and reduces apoptosis, the process by which damaged cells are removed.
  2. Adipokines. Leptin, which promotes cell proliferation, rises. Adiponectin, which is anti-inflammatory and protective, falls.
  3. Chronic low-grade inflammation. Immune cells in fat tissue release TNF-α and IL-6. These activate the NF-κB and STAT3 pathways and promote DNA damage.
  4. Gut dysbiosis. Harmful bacteria such as Fusobacterium nucleatum, colibactin-producing Escherichia coli (pks+) and enterotoxigenic Bacteroides fragilis become more abundant.

Obesity does not cause a tumour on its own. Instead, together with a Western-style diet, it creates an environment that speeds up the progression from a benign polyp (adenoma) to a carcinoma.

The gut microbiome: breakthroughs from 2024 to 2026

The gut microbiome links obesity, diet and colorectal cancer, and recent research has brought it to the centre of the story.

In April 2025, a study in Nature led by Marcos Díaz-Gay, now at Spain’s National Cancer Research Centre (CNIO), analysed 981 colorectal cancer genomes from 11 countries. The mutational signature left by colibactin, a toxin made by certain strains of E. coli, was 3.3 times more common in people diagnosed before 40 than in those diagnosed after 70. These mutations appear early in tumour development, which points to exposure in childhood.

In 2024, another Nature study showed that only one subgroup of Fusobacterium nucleatum, known as clade C2, dominates the tumour environment and increases adenoma formation in mice.

Obesity and low-fibre diets reduce microbial diversity and deplete the bacteria that produce butyrate, a short-chain fatty acid that nourishes colon cells and helps regulate inflammation. For colleagues, this is the key point: the microbiome is not only a marker of risk but a realistic target for nutritional treatment.

Diet: the strongest lever we have

The eating pattern that promotes obesity is the same one that harms the colon.

Foods that increase risk. IARC classifies processed meat as a Group 1 carcinogen, with risk increasing by 18% for every 50 g eaten per day. Red meat is “probably carcinogenic” (Group 2A), with risk increasing by 17% per 100 g a day. The mechanisms are directly relevant to food safety: N-nitroso compounds and nitrites, haem iron, and heterocyclic amines formed during high-temperature cooking.

New evidence also implicates ultra-processed foods. A study published in JAMA Oncology in 2025 followed 29,105 women in the Nurses’ Health Study II. Those with the highest intake had a 45% higher risk of early-onset conventional adenomas, the polyps that can develop into cancer, than those with the lowest intake.

Foods that protect. Every additional 10 g of fibre per day lowers colorectal cancer risk by around 10%, and three daily servings of wholegrains lower it by about 17%. Fibre increases butyrate production and shortens the time the gut lining spends in contact with carcinogens.

The speed of this effect is remarkable. In a diet-swap study by O’Keefe and colleagues, African Americans switched to a traditional high-fibre, low-fat African diet for two weeks, while rural Africans switched to a Western diet. On the high-fibre diet, colonic butyrate rose 2.5-fold and markers of inflammation and cell proliferation fell. The Western diet produced the opposite effect.

Legumes deserve special attention. In the BE GONE trial (2023), 48 adults with obesity and a history of colorectal polyps or cancer added one cup of beans a day for eight weeks. Their microbial diversity increased, along with beneficial bacteria such as Faecalibacterium and Bifidobacterium. These benefits were lost when they stopped. Variety also matters, because each legume provides a different fibre: resistant starch in lentils, raffinose in chickpeas and pectins in beans. Eating 30 or more different plant foods a week is associated with greater microbial diversity.

Finally, research at the Universidad de Burgos found that oleic acid, the main fat in olive oil, inhibits calcium entry in human colorectal adenocarcinoma cells. This is a laboratory finding, but it fits well with the Mediterranean pattern: varied legumes, vegetables and wholegrains dressed with extra virgin olive oil.

The obesity paradox, and why muscle matters

Some studies suggest that people who are overweight live longer after a colorectal cancer diagnosis. This “obesity paradox” largely disappears once we measure body composition. The C-SCANS study analysed CT scans from 3,262 patients with non-metastatic colorectal cancer: 42% had sarcopenia, and women with low muscle and high fat had a 64% higher risk of death (HR 1.64). BMI hides sarcopenic obesity, which is why lean mass should be measured.

In 2025, the phase 3 CHALLENGE trial, published in the New England Journal of Medicine, provided the strongest evidence yet. Among 889 people treated for colon cancer, a three-year structured exercise programme reduced the risk of recurrence, new cancer or death by 28% (HR 0.72). Five-year disease-free survival was 80.3% compared with 73.9%, and eight-year overall survival was 90.3% compared with 83.2%. Nutrition and exercise work best together, especially to protect muscle.

What about GLP-1 weight-loss medicines?

Many patients ask about semaglutide and similar drugs. A 2026 meta-analysis of randomised trials found no increase in gastrointestinal cancer risk with GLP-1 receptor agonists, which is reassuring. Several large observational studies suggest a possibly lower colorectal cancer risk, but these cannot prove cause and effect. Patients on these drugs also tend to have more colonoscopies. If you use these medicines, adequate protein and strength training are essential to avoid losing muscle along with fat.

Practical prevention: an evidence-based plan

woman with colorectal cancer concept on the pink backgorund
  • Measure your waist, not just your weight, and aim to reduce abdominal fat.
  • Eat at least 30 g of fibre a day, from legumes, wholegrains, vegetables, fruit, nuts and seeds.
  • Include legumes daily and vary them, aiming for 30 or more different plants each week.
  • Limit red meat and avoid processed meat; the World Cancer Research Fund recommends no more than about three portions (350 to 500 g cooked) of red meat a week.
  • Reduce ultra-processed foods and use extra virgin olive oil as your main fat.
  • Limit alcohol, which is an established risk factor.
  • Stay active and build muscle with regular aerobic and resistance exercise.
  • Take part in screening. Faecal immunochemical (FIT) testing saves lives.

Do not ignore warning signs at any age: blood in the stool, a persistent change in bowel habit, unexplained weight loss, iron-deficiency anaemia or ongoing abdominal pain. See your doctor promptly. Being under 50 does not rule out bowel cancer.

How Smart Nutrition International can help

At Smart Nutrition International (SNI), I work with patients online using a three-phase approach: an anti-inflammatory phase, microbiota modulation, and maintenance. I combine body composition assessment with personalised, evidence-based nutrition plans for weight management, gut health and oncology support.

Frequently asked questions

Does obesity cause colorectal cancer? Obesity does not cause colorectal cancer directly. It creates a hormonal, inflammatory and microbial environment that speeds up the progression from polyp to cancer, raising risk by around 30%.

Why is colorectal cancer increasing in young adults? The causes are still being studied. Rising obesity, ultra-processed diets, low fibre intake and early-life exposure to colibactin-producing gut bacteria are among the leading explanations.

Which foods help protect against bowel cancer? Legumes, wholegrains, vegetables, fruit, nuts and extra virgin olive oil. Variety supports a diverse, butyrate-producing microbiome.

Is waist size more important than BMI? For colorectal cancer, yes. Waist circumference reflects visceral fat and is a stronger predictor of risk than BMI.

This article is for general information and does not replace individual medical advice. If you have symptoms or a family history of colorectal cancer, please speak to your doctor.

References

  1. Lauby-Secretan B, et al. Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-8.
  2. Ma Y, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013;8(1):e53916.
  3. Liu PH, et al. Association of obesity with risk of early-onset colorectal cancer among women. JAMA Oncol. 2019;5(1):37-44.
  4. Caan BJ, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS Study). Cancer Epidemiol Biomarkers Prev. 2017;26(7):1008-15.
  5. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690-704.
  6. Bouvard V, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 2015;16(16):1599-600.
  7. Aune D, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis. BMJ. 2011;343:d6617.
  8. O’Keefe SJD, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. 2015;6:6342.
  9. Kyrgiou M, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477.
  10. SEOM, REDECAN. Las cifras del cáncer en España 2026. Madrid: SEOM; 2026.
  11. Díaz-Gay M, et al. Geographic and age variations in mutational processes in colorectal cancer. Nature. 2025;643(8070):230-40. PubMed
  12. Zepeda-Rivera M, et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature. 2024;628(8007):424-32.
  13. McDonald D, et al. American Gut: an open platform for citizen science microbiome research. mSystems. 2018;3(3):e00031-18.
  14. Zhang X, et al. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine. 2023;98:104873.
  15. Carrillo C, Cavia MM, Alonso-Torre SR. Oleic acid inhibits store-operated calcium entry in human colorectal adenocarcinoma cells. Eur J Nutr. 2012;51(6):677-84.
  16. Body mass index and early-onset colorectal cancer risk: a systematic review and cohort-based meta-analysis. Scand J Gastroenterol. 2026;61(4):383-396. PubMed
  17. Khattab O, et al. Obesity as a risk factor for early-onset colorectal cancer: evidence from a nationally representative database. World J Clin Oncol. 2025;16(7):108220.
  18. Global, regional, and national burden of early-onset colorectal cancer attributable to high BMI (1990–2021). Front Med. 2025;12:1631392.
  19. Wang C, et al. Ultraprocessed food consumption and risk of early-onset colorectal cancer precursors among women. JAMA Oncol. 2026;12(1):49-57. PubMed
  20. Courneya KS, et al. Structured exercise after adjuvant chemotherapy for colon cancer (CHALLENGE trial, NCT00819208). N Engl J Med. 2025.
  21. Wali AF, et al. Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies. Front Pharmacol. 2026.

Services

Scroll to Top